Ipsen Past Earnings Performance
Past criteria checks 5/6
Ipsen has been growing earnings at an average annual rate of 23.9%, while the Pharmaceuticals industry saw earnings declining at 2.4% annually. Revenues have been growing at an average rate of 6.2% per year. Ipsen's return on equity is 16.5%, and it has net margins of 19.3%.
Key information
23.9%
Earnings growth rate
24.0%
EPS growth rate
Pharmaceuticals Industry Growth | 14.1% |
Revenue growth rate | 6.2% |
Return on equity | 16.5% |
Net Margin | 19.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ipsen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 3,435 | 664 | 1,157 | 653 |
31 Mar 24 | 3,371 | 641 | 1,146 | 636 |
31 Dec 23 | 3,306 | 617 | 1,135 | 619 |
30 Jun 23 | 3,282 | 406 | 1,105 | 528 |
31 Mar 23 | 3,219 | 500 | 1,072 | 487 |
31 Dec 22 | 3,156 | 593 | 1,039 | 445 |
30 Sep 22 | 3,053 | 656 | 1,007 | 436 |
30 Jun 22 | 2,950 | 719 | 975 | 427 |
31 Mar 22 | 2,849 | 675 | 946 | 425 |
31 Dec 21 | 2,749 | 631 | 916 | 424 |
30 Sep 21 | 2,712 | 626 | 923 | 422 |
30 Jun 21 | 2,676 | 622 | 931 | 420 |
31 Mar 21 | 2,681 | 585 | 951 | 413 |
31 Dec 20 | 2,686 | 548 | 972 | 406 |
30 Sep 20 | 2,697 | 249 | 986 | 404 |
30 Jun 20 | 2,707 | -50 | 1,000 | 403 |
31 Mar 20 | 2,700 | -53 | 1,010 | 396 |
31 Dec 19 | 2,693 | -55 | 1,021 | 389 |
30 Sep 19 | 2,605 | 176 | 1,003 | 363 |
30 Jun 19 | 2,516 | 406 | 986 | 337 |
31 Mar 19 | 2,432 | 397 | 970 | 319 |
31 Dec 18 | 2,348 | 388 | 954 | 302 |
30 Sep 18 | 2,258 | 365 | 931 | 292 |
30 Jun 18 | 2,167 | 343 | 909 | 281 |
31 Mar 18 | 2,090 | 307 | 883 | 274 |
31 Dec 17 | 2,012 | 270 | 858 | 266 |
30 Sep 17 | 1,923 | 243 | 821 | 264 |
30 Jun 17 | 1,834 | 217 | 785 | 262 |
31 Mar 17 | 1,753 | 221 | 752 | 247 |
31 Dec 16 | 1,671 | 226 | 719 | 231 |
30 Sep 16 | 1,623 | 229 | 703 | 214 |
30 Jun 16 | 1,575 | 233 | 687 | 196 |
31 Mar 16 | 1,548 | 211 | 676 | 194 |
31 Dec 15 | 1,520 | 189 | 666 | 193 |
30 Sep 15 | 1,468 | 165 | 651 | 192 |
30 Jun 15 | 1,416 | 140 | 636 | 191 |
31 Mar 15 | 1,374 | 147 | 606 | 189 |
31 Dec 14 | 1,332 | 154 | 577 | 187 |
30 Sep 14 | 1,310 | 155 | 557 | 190 |
30 Jun 14 | 1,287 | 156 | 537 | 193 |
31 Mar 14 | 1,284 | 149 | 543 | 194 |
31 Dec 13 | 1,282 | 142 | 549 | 196 |
Quality Earnings: 0MH6 has high quality earnings.
Growing Profit Margin: 0MH6's current net profit margins (19.3%) are higher than last year (12.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0MH6's earnings have grown significantly by 23.9% per year over the past 5 years.
Accelerating Growth: 0MH6's earnings growth over the past year (63.4%) exceeds its 5-year average (23.9% per year).
Earnings vs Industry: 0MH6 earnings growth over the past year (63.4%) exceeded the Pharmaceuticals industry 4.5%.
Return on Equity
High ROE: 0MH6's Return on Equity (16.5%) is considered low.